$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Published by Global Markets Direct: 16 Nov 2016 | 32482 | In Stock

Introduction

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)

- The report reviews Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

  • Table of Contents

    Table of Contents 2

    List of Tables 8

    List of Figures 9

    Introduction 10

    Global Markets Direct Report Coverage 10

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) Overview 11

    Therapeutics Development 12

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Stage of Development 12

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Therapy Area 13

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Indication 14

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Products Glance 17

    Late Stage Products 17

    Early Stage Products 18

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Companies 19

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Products under Development by Universities/Institutes 30

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Therapeutics Assessment 32

    Assessment by Monotherapy/Combination Products 32

    Assessment by Mechanism of Action 33

    Assessment by Route of Administration 35

    Assessment by Molecule Type 37

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Companies Involved in Therapeutics Development 39

    Advenchen Laboratories, LLC 39

    Amgen Inc. 40

    ArQule, Inc. 41

    Astellas Pharma Inc. 42

    AstraZeneca Plc 43

    Asubio Pharma Co., Ltd. 44

    AVEO Pharmaceuticals, Inc. 45

    Bayer AG 46

    BioArctic AB 47

    Boehringer Ingelheim GmbH 48

    Bristol-Myers Squibb Company 49

    CardioVascular BioTherapeutics, Inc. 50

    Celon Pharma Sp. z o.o. 51

    Debiopharm International SA 52

    Eddingpharm 53

    Eisai Co., Ltd. 54

    Eli Lilly and Company 56

    F. Hoffmann-La Roche Ltd. 57

    Hutchison MediPharma Limited 58

    Incyte Corporation 59

    Johnson & Johnson 60

    Les Laboratoires Servier SAS 61

    Metacrine Inc 62

    Novartis AG 63

    OncoMax 64

    Principia Biopharma Inc. 65

    Teva Pharmaceutical Industries Ltd. 66

    Vichem Chemie Research Ltd. 67

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Drug Profiles 68

    Aea-25 - Drug Profile 68

    Product Description 68

    Mechanism Of Action 68

    R&D Progress 68

    Aea-4 - Drug Profile 69

    Product Description 69

    Mechanism Of Action 69

    R&D Progress 69

    ARQ-087 - Drug Profile 70

    Product Description 70

    Mechanism Of Action 70

    R&D Progress 70

    ASP-5878 - Drug Profile 72

    Product Description 72

    Mechanism Of Action 72

    R&D Progress 72

    AZD-4547 - Drug Profile 73

    Product Description 73

    Mechanism Of Action 73

    R&D Progress 73

    BAY-1163877 - Drug Profile 75

    Product Description 75

    Mechanism Of Action 75

    R&D Progress 75

    BMS-986036 - Drug Profile 76

    Product Description 76

    Mechanism Of Action 76

    R&D Progress 76

    brivanib alaninate - Drug Profile 77

    Product Description 77

    Mechanism Of Action 77

    R&D Progress 77

    CEP-11981 - Drug Profile 80

    Product Description 80

    Mechanism Of Action 80

    R&D Progress 80

    CPL-043 - Drug Profile 81

    Product Description 81

    Mechanism Of Action 81

    R&D Progress 81

    CVBT-141B - Drug Profile 82

    Product Description 82

    Mechanism Of Action 82

    R&D Progress 82

    CVBT-141C - Drug Profile 84

    Product Description 84

    Mechanism Of Action 84

    R&D Progress 84

    CVBT-141D - Drug Profile 85

    Product Description 85

    Mechanism Of Action 85

    R&D Progress 85

    CVBT-141H - Drug Profile 86

    Product Description 86

    Mechanism Of Action 86

    R&D Progress 86

    Debio-1347 - Drug Profile 87

    Product Description 87

    Mechanism Of Action 87

    R&D Progress 87

    Drugs to Agonize Fibroblast Growth Factor Receptor 1 for Type 2 Diabetes - Drug Profile 89

    Product Description 89

    Mechanism Of Action 89

    R&D Progress 89

    E-7090 - Drug Profile 90

    Product Description 90

    Mechanism Of Action 90

    R&D Progress 90

    EDP-317 - Drug Profile 91

    Product Description 91

    Mechanism Of Action 91

    R&D Progress 91

    erdafitinib - Drug Profile 92

    Product Description 92

    Mechanism Of Action 92

    R&D Progress 92

    FGF-1 Program - Drug Profile 94

    Product Description 94

    Mechanism Of Action 94

    R&D Progress 94

    HMPL-012 - Drug Profile 95

    Product Description 95

    Mechanism Of Action 95

    R&D Progress 95

    HMPL-453 - Drug Profile 98

    Product Description 98

    Mechanism Of Action 98

    R&D Progress 98

    INCB-54828 - Drug Profile 99

    Product Description 99

    Mechanism Of Action 99

    R&D Progress 99

    infigratinib - Drug Profile 100

    Product Description 100

    Mechanism Of Action 100

    R&D Progress 100

    lenvatinib mesylate - Drug Profile 102

    Product Description 102

    Mechanism Of Action 102

    R&D Progress 102

    lucitanib - Drug Profile 115

    Product Description 115

    Mechanism Of Action 115

    R&D Progress 115

    LY-2874455 - Drug Profile 118

    Product Description 118

    Mechanism Of Action 118

    R&D Progress 118

    Monoclonal Antibody to Antagonize FGFR1 for Cancer - Drug Profile 119

    Product Description 119

    Mechanism Of Action 119

    R&D Progress 119

    nintedanib - Drug Profile 120

    Product Description 120

    Mechanism Of Action 120

    R&D Progress 120

    OMRCA-01 - Drug Profile 131

    Product Description 131

    Mechanism Of Action 131

    R&D Progress 131

    pazopanib hydrochloride - Drug Profile 133

    Product Description 133

    Mechanism Of Action 133

    R&D Progress 133

    pazopanib hydrochloride + pembrolizumab - Drug Profile 141

    Product Description 141

    Mechanism Of Action 141

    R&D Progress 141

    PRN-1371 - Drug Profile 142

    Product Description 142

    Mechanism Of Action 142

    R&D Progress 142

    Recombinant Protein to Agonize FGFR for Type 2 Diabetes - Drug Profile 143

    Product Description 143

    Mechanism Of Action 143

    R&D Progress 143

    Recombinant Proteins to Agonize FGFR for Metabolic Disorders - Drug Profile 144

    Product Description 144

    Mechanism Of Action 144

    R&D Progress 144

    regorafenib - Drug Profile 145

    Product Description 145

    Mechanism Of Action 145

    R&D Progress 145

    RG-7992 - Drug Profile 156

    Product Description 156

    Mechanism Of Action 156

    R&D Progress 156

    S-49076 - Drug Profile 157

    Product Description 157

    Mechanism Of Action 157

    R&D Progress 157

    SC-0806 - Drug Profile 159

    Product Description 159

    Mechanism Of Action 159

    R&D Progress 159

    Small Molecules to Antagonize Pan FGFR for Oncology - Drug Profile 160

    Product Description 160

    Mechanism Of Action 160

    R&D Progress 160

    SUN-11602 - Drug Profile 161

    Product Description 161

    Mechanism Of Action 161

    R&D Progress 161

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Dormant Projects 162

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Discontinued Products 167

    Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Featured News & Press Releases 170

    Nov 07, 2016: Bayer Submits Supplemental New Drug Application for Stivarga (regorafenib) for Advanced Liver Cancer 170

    Nov 07, 2016: Regorafenib from Bayer Submitted to Health Authorities Seeking Approval in Second-Line Treatment of Liver Cancer 171

    Oct 26, 2016: Eisais LENVIMA (lenvatinib) Nominated for Galien Foundations Best Pharmaceutical Product 172

    Oct 24, 2016: Efficacy of Ofev (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST 173

    Oct 12, 2016: Preliminary Phase Ib Clinical Study Results for Lenvatinib in Combination with Pembrolizumab in Selected Solid Tumors Presented at ESMO 2016 174

    Oct 09, 2016: ESMO 2016: Lenvatinib Shows Promising Activity in Patients with RET-Positive Adenocarcinoma of the Lung 175

    Oct 09, 2016: People with an Advanced Form of Thyroid Cancer Now Able to Benefit From Lenvima (lenvatinib) in Scotland 176

    Oct 09, 2016: Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO 178

    Oct 08, 2016: Phase I study of novel anti-cancer drug uses tumor mRNA expression to identify responders 178

    Sep 30, 2016: Eisai To Initiate Phase III Clinical Study Of Anticancer Agent Lenvatinib As Potential First-Line Therapy For Advanced Renal Cell Carcinoma 179

    Sep 29, 2016: Eisai To Present Latest Data On Lenvatinib At ESMO Congress 2016 180

    Sep 28, 2016: Bayer to Showcase Regorafenib at ESMO 2016 Congress 181

    Sep 28, 2016: Bayer presents New Data on BAY 1163877 at ESMO 2016 Congress 183

    Sep 21, 2016: Eisai to Present Updates on Lenvatinib in Two Types of Thyroid Cancer at 86th Annual Meeting of the American Thyroid Association 183

    Sep 15, 2016: Eisai Receives License For New Indication For Anticancer Agent Kisplyx (Lenvatinib Mesylate) For Treatment Of Advanced Renal Cell Carcinoma 185

    Appendix 186

    Methodology 186

    Coverage 186

    Secondary Research 186

    Primary Research 186

    Expert Panel Validation 186

    Contact Us 186

    Disclaimer 187

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

32482 | GMDHC0657TDB

Number of Pages

187

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017
Fibroblast Growth Factor Receptor 4 (CD334 or FGFR4 or EC 2.7.10.1) - Pipeline Review, H1 2017Summar...
13 Jun 2017 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Fibroblast Activation Protein (FAP or Seprase) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Activation Protein (FAP or Seprase) Inhibitors-Pipeline Insights, 2017”,...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Fibroblast Growth Factor (FGF) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor (FGF) Inhibitors-Pipeline Insights, 2017”, report provides...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Fibroblast Growth Factor 1 (FGF-1) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor 1 (FGF-1) Inhibitors-Pipeline Insights, 2017”, report prov...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor (FGFR) Agonists -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor Receptor (FGFR) Agonists-Pipeline Insights, 2017”, report ...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor (FGFR) Inhibitors -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor Receptor (FGFR) Inhibitors-Pipeline Insights, 2017”, repor...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists -Pipeline Insights, 2017
DelveInsight’s, “Fibroblast Growth Factor Receptor 1 (FGFR1) Agonists-Pipeline Insights, 2017”, repo...
30 May 2017 by Delve Insight USD $1,100 (normally
USD $1,250)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 or FGFR2 or EC 2.7.10.1) - Pipeline Review, H2 2016
Fibroblast Growth Factor Receptor 2 (Keratinocyte Growth Factor Receptor or K Sam or KGFR or CD332 o...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or FGFR3 or EC 2.7.10.1) - Pipeline Review, H2 2016
Fibroblast Growth Factor Receptor 3 (Tyrosine Kinase JTK4 or Hydroxyaryl Protein Kinase or CD333 or ...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2) - Pipeline Review, H2 2016
Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF...
09 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Fibroblast Growth Factor Receptor 1 (Basic Fibroblast Growth Factor Receptor 1 or Fms Like Tyrosine Kinase 2 or N Sam or Proto Oncogene c Fgr or CD331 or FLT2 or FGFR1 or EC 2.7.10.1) - Pipeline Review, H2 2016 [Published by Global Markets Direct] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...